Drug Discovery World

MARCH 21, 2023

We believe we have developed the first technology to design an organism that can’t be infected by any known virus,” said the study’s first author, Akos Nyerges, research fellow in genetics in the lab of George Church in the Blavatnik Institute at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering. “We

Engineering 130

Engineering Virus Research Medical Schools 130

Drug Discovery World

JULY 19, 2022

An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection. . The clinical trial has been launched by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate an investigational vaccine to prevent infection with Nipah virus. Official comments .

Clinical Trials 130

Clinical Trials Trials Virus Vaccine 130

Drug Discovery World

OCTOBER 24, 2022

New research suggests messenger RNA can be effectively used as a ‘universal’ therapy against different coronaviruses. . Rather than messenger RNA as a vaccine, this shows that mRNA can be used as a universal therapy against different coronaviruses,” said Gaurav Sahay, OSU and the Texas Biomedical Research Institute.

Treatment 100

Treatment RNA Protein Production Packaging 100

Drug Discovery World

JANUARY 11, 2024

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. Patients affected by the disease are found to also experience an imbalance of glutathione regulation, which is important for liver detoxification.

Disease 147

Disease Research RNA Therapies 147

Drug Discovery World

MAY 22, 2023

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Pharma is also keen to access next generation RNA platforms, such as self-amplifying RNAs derived from the genomes of positive-strand RNA viruses.

Pharma Companies 130

Pharma Companies RNA Therapies Virus 130

The Pharma Data

JANUARY 21, 2021

President Joe Biden has promised to re-energize the nation’s response to COVID-19, but one of his top pandemic advisors says that effort could be hamstrung by both the virus and the failings of the previous administration. Right now, the main focus is on helping distribute the vaccines, Osterholm said.

Vaccine 52

Vaccine Virus RNA Research 52

Drug Discovery World

JANUARY 21, 2024

As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay. As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay.

Vaccine 130

Vaccine Computational Chemistry Animal Testing Engineering 130

The Pharma Data

JANUARY 11, 2021

Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. based company has been in business for 10 years, but the COVID-19 vaccine was its first approved product. 18, 2020 ). It has already received $2.8

Vaccine 52

Vaccine Clinical Trials Virus RNA 52

Drug Discovery World

MAY 23, 2024

Reece Armstrong speaks to Samuel Deutsch , Chief Scientific Officer of Nutcracker Therapeutics about the RNA landscape and how it can benefit the development of immunotherapies. RA: What role does RNA play in the development of effective immunotherapies? SD: This is definitely a challenge.

RNA 147

RNA Therapies Engineering Disease 147

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

AUGUST 16, 2021

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

DECEMBER 3, 2020

The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. No serious adverse events related to the vaccine candidates studied were reported.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Drug Discovery World

SEPTEMBER 14, 2023

Vaccines were up 9.1% Moreover, in July 2023, AstraZeneca and Vaxess Technologies commenced a collaboration for the evaluation of a novel RNA-based pandemic influenza prototype vaccine in patch format. Specialty care grew 11.8% Chris Boshoff, M.D., As a result of these moves, William Pao, M.D.,

Vaccine 147

Vaccine FDA Approval Drugs Licensing 147

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. Changes in mutationally constrained epitopes are rare, as they can cause the virus to lose its ability to infect and replicate, essentially rendering it unable to propagate itself.

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

DECEMBER 16, 2020

Food and Drug Administration (FDA) advisory panel in regard to the COVID-19 vaccine from Moderna. The Vaccines and Related Biological Products Advisory Committee will be determining whether the product should be authorized for emergency use, according to CNBC. The vote itself is not slated to take place until after 3 p.m.

Vaccine 52

Vaccine Immune Response FDA FDA Approval 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

AUGUST 16, 2021

The antiviral agent incorporates RNA-like building blocks into the RNA genome of the virus. If this genetic material is further replicated, defective RNA copies are produced and the pathogen can no longer spread. ” Mutations in the genome stop the virus.

RNA 52

RNA Virus Clinical Trials Drugs 52

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. Sanofi and GSK now plan to enroll more than 35,000 participants I a phase 3 study to evaluate the vaccine’s efficacy against the original SARS?CoV?2

Vaccine 40

Vaccine Immune Response RNA Virus 40

The Pharma Data

DECEMBER 10, 2020

–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. 11, 2020 02:48 UTC. CULVER CITY, Calif.–( This press release features multimedia.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

DECEMBER 3, 2020

The Pfizer – BioNTech and Moderna ’s COVID-19 vaccines are currently being reviewed for possible Emergency Use Authorization (EUA) by the U.S. On Tuesday, the Pfizer-BioNTech vaccine was granted temporary authorization in the UK and dosing will begin next week. Pfizer gets its raw materials for the vaccine from the U.S.

Vaccine 52

Vaccine Government RNA FDA 52

The Pharma Data

DECEMBER 19, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. Healthcare workers have been on the front lines of the fight against the virus and are an inspiration to us all.

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

Drug Target Review

MAY 22, 2024

What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context.

Therapies 58

Therapies RNA Protein Expression DNA 58

The Pharma Data

MARCH 11, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

OCTOBER 23, 2020

The authors recommended viral load thresholds of 1,000 IU for hepatitis B virus (HBV), hepatitis C virus (HCV) RNA undetectable for HCV, and suppressed viral RNA for HIV for determining any restrictions on HCP practice.

RNA 52

RNA Virus Vaccine Hospitals 52

The Pharma Data

DECEMBER 18, 2020

Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. Hahn , M.D.

Vaccine 52

Vaccine FDA Clinical Trials FDA Approval 52

PerkinElmer

JUNE 14, 2021

The speed at which researchers developed effective vaccines to prevent the spread of COVID-19 required unprecedented international cooperation on a scale never seen before. Rollout of approved vaccines is underway in many countries across the globe, giving people hope that the end to the pandemic is finally in sight.

Virus 52

Virus RNA Vaccine Treatment 52

The Pharma Data

MARCH 8, 2022

The ongoing SARS-CoV-2 pandemic has caused an imminent urge for both antiviral therapeutical drugs and vaccines. While the development of vaccines was accomplished in a remarkably short timeframe, the identification of direct antiviral treatments has progressed comparatively slowly. Camouflage protects virus from immune system.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. Gene Delivery Systems Genetic material, in the form of DNA or RNA, does not easily enter cells without the aid of a delivery system.

Engineering 52

Engineering Clinical Research Research Virus 52

The Pharma Data

NOVEMBER 17, 2020

After getting the virus under control, California Gov. Until now, Reynolds had ignored infectious disease experts who say masks are one of the most effective tools to control the spread of the virus, the Post reported. Moderna’s COVID Vaccine Shows 94.5% effectiveness. In some good news, Moderna Inc. percent effective.

Vaccine 52

Vaccine Virus RNA Hospitals 52

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 130

RNA Vaccine Drugs Disease 130

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. mRNA is a molecule made up of a single strand of ribonucleic acid (RNA). Reece Armstrong explores the potential and future opportunities for mRNA-based therapies.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

The Pharma Data

NOVEMBER 16, 2020

The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group. The majority of adverse events were mild or moderate in severity.

Vaccine 52

Vaccine FDA Clinical Trials Disease 52

The Pharma Data

NOVEMBER 18, 2020

Lab tests that look for the coronavirus’s genetic material using a technique called polymerase chain reaction (PCR) are still considered the gold standard for detecting the virus. ” COVID Vaccines Move Closer to Emergency Use Approval. announced earlier this week that early results show its coronavirus vaccine is 94.5

FDA Approval 52

FDA Approval FDA Vaccine Virus 52

Broad Institute

MAY 14, 2024

William Studier for development of widely used protein- and RNA-production platform By Corie Lok May 14, 2024 Breadcrumb Home Merkin Prize in Biomedical Technology awarded to F. Merkin Prize in Biomedical Technology for his development of an efficient, scalable method of producing RNA and proteins in the laboratory.

RNA 84

RNA Production Molecular Biology Laboratories 84

PLOS: DNA Science

JULY 27, 2023

That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus.

Disease 69

Disease DNA Virus RNA 69

PerkinElmer

AUGUST 18, 2020

This is especially applicable to labs involved in the development of highly sought-after viral therapeutics and vaccines. The time sensitivity of virus research, combined with an increasing complexity of bench tasks, can make it helpful for labs to increase automaticity of experiments.

Virus 52

Virus Vaccine RNA DNA 52